poisar

Stocks · News reference

Acumen Announces New Findings Presented At AAIC 2026; JCR Collaboration Shows Improved Brain Penetration Of Anti‑Aβo Antibodies Via Transferrin Receptor Delivery In Mouse And Primate Models

Benzinga Newsdesk

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABOS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

    Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.

    HALOABOS
  4. SEC EDGAR

    8-K filing — Acumen Pharmaceuticals, Inc. (ABOS)

    Filed: 2026-08-12 AccNo: 0001628280-26-055940 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    ABOS